L755507

Catalog No.S7974 Batch:S797401

Print

Technical Data

Formula

C30H40N4O6S
Molecular Weight 584.73 CAS No. 159182-43-1
Solubility (25°C)* In vitro DMSO 100 mg/mL (171.01 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description L-755,507 is characterized as a potent and selective β3 adrenergic receptor partial agonist with EC50 of 0.43 nM. It is also recently identified to enhance CRISPR-mediated homology-directed repair (HDR) efficiency in human induced pluripotent stem cells (iPSCs) and other cell types.
Targets
β3 adrenergic receptor [1]
0.43 nM(EC50)
In vitro L-755,507 displays an excellent activity profile as an extremely potent human β3 adrenergic receptor agonist (β3 EC50 0.43 nM), with >440-fold selectivity over β1 and β2 binding[1]. L755507 causes a robust concentration-dependent increase in cAMP accumulation in CHO-K1 cells expressing human β3-adrenoceptors(pEC50 values of 12.3)[4]. In a recent study employing a high-throughput screen to identify chemicals capable of modulating HR-mediated genome editing, L-755507 is identified that could enhance HR repair by up to ninefold[3].
In vivo Acute exposure of rhesus monkeys to L-755,507 elicits lipolysis and metabolic rate elevation, and that chronic exposure increases uncoupling protein 1 expression in rhesus brown adipose tissue[2].

Protocol (from reference)

Cell Assay:

[3]
  • Cell lines

    cancer cell lines(K562 and HeLa), suspension cells (K562), primary neonatal cells (HUVEC and fibroblast CRL-2097), and human ESC derived cells (neural stem cells)

  • Concentrations

    5 μM

  • Incubation Time

    24 hours

  • Method

    --
Animal Study:

[2]
  • Animal Models

    Male lean rhesus monkeys

  • Dosages

    3 mg/kg

  • Administration

    i.v.

Selleck's L755507 has been cited by 5 publications

In situ correction of various β-thalassemia mutations in human hematopoietic stem cells [ Front Cell Dev Biol, 2023, 11:1276890] PubMed: 38333188
Identifying key underlying regulatory networks and predicting targets of orphan C/D box SNORD116 snoRNAs in Prader-Willi syndrome [ bioRxiv, 2023, 10.1101/2023.10.03.560773] PubMed: 37873184
An effective double gene knock-in strategy using small-molecule L755507 in the medaka fish (Oryzias latipes) [ Genesis, 2022, 60(1-2):e23465] PubMed: 35072325
Construction of Synthetic Nanobody Library in Mammalian Cells by dsDNA-Based Strategies* [ Chembiochem, 2021, 22(20):2957-2965] PubMed: 34411391
Functional Interrogation of Lynch Syndrome Associated MSH2 Missense Variants via CRISPR-Cas9 Gene Editing in Human Embryonic Stem Cells [ Hum Mutat, 2019, 10.1002/humu.23848] PubMed: 31237724

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.